RIA Advisory Group LLC Purchases New Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

RIA Advisory Group LLC acquired a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 25,620 shares of the company’s stock, valued at approximately $342,000.

Other institutional investors have also recently modified their holdings of the company. CIBC Asset Management Inc bought a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $259,000. Victory Capital Management Inc. grew its holdings in shares of Perspective Therapeutics by 328.7% during the third quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock worth $674,000 after purchasing an additional 38,690 shares during the last quarter. WealthPlan Investment Management LLC acquired a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $4,530,000. Los Angeles Capital Management LLC acquired a new position in Perspective Therapeutics in the 3rd quarter valued at approximately $153,000. Finally, Hills Bank & Trust Co bought a new stake in shares of Perspective Therapeutics in the third quarter worth $13,722,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock traded down $1.04 during trading on Friday, hitting $7.88. The stock had a trading volume of 1,849,338 shares, compared to its average volume of 695,032. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05. The company’s 50-day moving average price is $12.55.

Analyst Ratings Changes

CATX has been the topic of several recent analyst reports. Oppenheimer restated an “outperform” rating and issued a $22.00 target price on shares of Perspective Therapeutics in a report on Friday, October 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $20.00 target price on shares of Perspective Therapeutics in a research note on Thursday, October 24th. Finally, Bank of America assumed coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price target for the company. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $21.57.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.